WO1997032593A2 - Composition contenant des iso-flavonoides et des lignanes - Google Patents
Composition contenant des iso-flavonoides et des lignanes Download PDFInfo
- Publication number
- WO1997032593A2 WO1997032593A2 PCT/GB1997/000622 GB9700622W WO9732593A2 WO 1997032593 A2 WO1997032593 A2 WO 1997032593A2 GB 9700622 W GB9700622 W GB 9700622W WO 9732593 A2 WO9732593 A2 WO 9732593A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- lignans
- flavonoids
- iso
- component
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 229930013032 isoflavonoid Natural products 0.000 title claims abstract description 30
- 150000003817 isoflavonoid derivatives Chemical class 0.000 title claims abstract description 30
- 235000012891 isoflavonoids Nutrition 0.000 title claims abstract description 30
- 229930013686 lignan Natural products 0.000 title claims abstract description 29
- 150000005692 lignans Chemical class 0.000 title claims abstract description 29
- 235000009408 lignans Nutrition 0.000 title claims abstract description 29
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 17
- 235000014510 cooky Nutrition 0.000 claims abstract description 16
- 201000011510 cancer Diseases 0.000 claims abstract description 14
- HVDGDHBAMCBBLR-UHFFFAOYSA-N Enterolactone Natural products OC1=CC=CC(CC2C(C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-UHFFFAOYSA-N 0.000 claims abstract description 12
- HVDGDHBAMCBBLR-WMLDXEAASA-N enterolactone Chemical compound OC1=CC=CC(C[C@@H]2[C@H](C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-WMLDXEAASA-N 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 11
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 10
- 244000068988 Glycine max Species 0.000 claims abstract description 10
- 235000004426 flaxseed Nutrition 0.000 claims abstract description 10
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 claims abstract description 9
- 230000003028 elevating effect Effects 0.000 claims abstract description 9
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000006539 genistein Nutrition 0.000 claims abstract description 5
- 229940045109 genistein Drugs 0.000 claims abstract description 5
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims abstract description 5
- 235000015895 biscuits Nutrition 0.000 claims abstract description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 9
- DWONJCNDULPHLV-HOTGVXAUSA-N Enterodiol Chemical compound C([C@@H](CO)[C@H](CO)CC=1C=C(O)C=CC=1)C1=CC=CC(O)=C1 DWONJCNDULPHLV-HOTGVXAUSA-N 0.000 claims description 9
- AOJXPBNHAJMETF-UHFFFAOYSA-N Enterodiol Natural products OCC(Cc1ccc(O)cc1)C(CO)Cc2ccc(O)cc2 AOJXPBNHAJMETF-UHFFFAOYSA-N 0.000 claims description 9
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 8
- 206010027304 Menopausal symptoms Diseases 0.000 claims description 8
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 8
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims description 8
- 235000007240 daidzein Nutrition 0.000 claims description 4
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 abstract description 3
- 208000030499 combat disease Diseases 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 description 21
- 235000007238 Secale cereale Nutrition 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 11
- 238000010411 cooking Methods 0.000 description 10
- 238000002156 mixing Methods 0.000 description 9
- 230000037213 diet Effects 0.000 description 8
- 239000006188 syrup Substances 0.000 description 7
- 235000020357 syrup Nutrition 0.000 description 7
- 244000075850 Avena orientalis Species 0.000 description 6
- 235000007319 Avena orientalis Nutrition 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- 241000220225 Malus Species 0.000 description 6
- 241000209140 Triticum Species 0.000 description 6
- 235000021307 Triticum Nutrition 0.000 description 6
- 240000008042 Zea mays Species 0.000 description 6
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 6
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 6
- 235000021016 apples Nutrition 0.000 description 6
- 235000005822 corn Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- WUADCCWRTIWANL-UHFFFAOYSA-N biochanin A Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O WUADCCWRTIWANL-UHFFFAOYSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000008094 contradictory effect Effects 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 206010071445 Bladder outlet obstruction Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000010235 enterohepatic circulation Effects 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940072254 proscar Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
- A21D13/00—Finished or partly finished bakery products
- A21D13/80—Pastry not otherwise provided for elsewhere, e.g. cakes, biscuits or cookies
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/36—Vegetable material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
Definitions
- the present invention relates to a composition and method of treatment useful to combat disease states, such as cancer, especially before such disease states are clinically detectable or alternatively when they are less advanced.
- the "Western diet” has been considered to be one in which the fat consumption is high, whereas the "fibre” intake is low.
- the proportion of the total calorific intake related to fat in the more vegetarian-style “Eastern diet” is comparatively low and the "fibre”, and fruit and vegetable content of the diet is high, or high in relation to fat intake (see Yu et al, Int J. Epidemiol 127 : 42-49 (1988)).
- Western diseases such as cancers of the breast and of the prostrate gland, and also colorectal carcinoma and cardiovascular disease, are associated with fat as a causative factor.
- the present invention provides a composition to combat cancer (especially breast cancer), benign prostatic hyperplasia, cardiovascular disease and post-menopausal symptoms, said composition being capable of elevating the levels of iso-flavonoids and lignans (eg enterolactone and/or enterodiol) in the body.
- cancer especially breast cancer
- benign prostatic hyperplasia cardiovascular disease
- post-menopausal symptoms said composition being capable of elevating the levels of iso-flavonoids and lignans (eg enterolactone and/or enterodiol) in the body.
- lignans eg enterolactone and/or enterodiol
- administration of the composition causes an increase in the amount of available iso-flavonoids and lignans, ie of iso-flavonoids and lignans circulating in the bloodstream.
- iso-flavonoids we refer to isoflavonic phyto-oestrogens .
- the daily dosage of said composition is selected so that the levels of iso-flavonoids and lignans (eg enterolactone and/or enterodiol) are maintained at therapeutically useful concentrations.
- the composition may provide a daily dosage of 10-50 mg iso-flavonoids, conveniently 20-30 mg iso- flavonoids.
- the composition may further provide a daily dosage of 2-5 mg lignans, conveniently 3-4 mg lignans.
- composition of the present invention may be used as a prophylactic (ie preventative) measure or may be used to treat, hinder or prevent existing cancer developments. In the latter case, the composition of the present invention maybe used in combination with other conventional treatments, such as radiotherapy for cancer etc.
- the composition of the present invention is presented in the form of a foodstuff, conveniently in the form of a biscuit or "cookie".
- the composition may contain a soya-based component and a flaxseed-based or rye-based component as major ingredients; since these components are capable of providing the iso-flavonoids and lignans (such as enterolactone and enterodiol) respectively.
- the composition further contains rye bran, which in combination with the flaxseed or rye, and soya-based components is particularly efficacious.
- Alternative ingredients which are also good sources of iso-flavonoids may be used to replace the soya-based component, whilst alternative ingredients which are good sources of enterolactone may be used instead of the flaxseed-based component.
- Rye is preferred as a source of lignans.
- the foodstuff will normally also contain other ingredients to produce a palatable product.
- the micro-flora in the gut of the patient breakdown or otherwise act upon the soya and flaxseed- or rye-based components, producing iso-flavonoids and lignans which are then absorbed and taken up into the bloodstream of the patient.
- the concentrations of iso-flavonoids and lignans in the patient's bloodstream is deliberately elevated.
- the composition contains 15% to 35% by weight of a soya based component (for example 20% to 30%, especially about 25% by weight), together with 8% to 16% by weight of a flaxseed based component (for example 11% to 13%, especially about 12% by weight) and /or 6% to 13% by weight of a rye based component (for example 8% to 10%, especially about 9% by weight).
- the composition provides 20-30 mg iso- flavonoids (preferably substantially genistein and daidzein) and 3-4 mg lignans per day per patient.
- a 25-30 g cookie made from ingredients including 8-10 g soya and a total of 4-8 g linseed flour and rye bran would provide the required amounts of iso-flavonoids and lignans .
- the composition of the present invention also contains a significant amount (for example 20-40% of the recommended daily intake, usually approximately 25% of the recommended daily intake) of fibre.
- a significant amount for example 20-40% of the recommended daily intake, usually approximately 25% of the recommended daily intake
- rye provides both the lignans required and also the fibre component.
- the fibre content of the cookie would typically be rye or wheat bran.
- the bran is believed to prevent the reabsorption of oestrogen by the gut - lowering plasma oestrogens by hindering reabsorption by the enterohepatic circulation.
- Lower plasma oestrogen may be effective in preventing breast cancer development.
- the concept relates to the marked differences in the incidence of breast and prostate cancer, clinical BPH (benign prostatic hyperplasia) and cardiovascular disease between the Asian countries where there is little incidence of these diseases, and the Western developed countries of Northern Europe and the USA, where these diseases are, except for BPH, principal killers.
- the composition essentially increases the levels of iso- flavonoids and lignans in the plasmas of Western people to those concentrations of both as measured in the plasma of Asian people and of lignans in vegetarians.
- composition could therefore favourably influence
- iso-flavonoid is genistein, but other iso-flavonoids may also be used. Mention may be made of daidzein, biochanin A and formonentein as being other iso-flavonoids of interest.
- angiogenesis inhibitor (preventing blood vessels growing out to support tumour growth) .
- the present invention provides a method of combatting cancer in a human or non-human (preferably mammalian) animal body, said method comprising elevating the levels of iso-flavonoids and lignans (eg enterolactone and/or enterodiol) in said body.
- iso-flavonoids and lignans eg enterolactone and/or enterodiol
- the present invention provides a method of relieving postmenopausal symptoms in a human or non-human (preferably mammalian) female animal body, said method comprising elevating the levels of iso- flavonoids and lignans (eg enterolactone and/or enterodiol) in said body.
- iso- flavonoids and lignans eg enterolactone and/or enterodiol
- the levels of iso-flavonoids and lignans are elevated in situ in the body to therapeutically useful levels, by the administration of a suitable source, for example a sufficient quantity of alternative or in addition to rye as a source of lignans.
- a suitable source for example a sufficient quantity of alternative or in addition to rye as a source of lignans.
- the iso-flavonoid and lignans eg enterolactone and/or enterodiol
- the iso-flavonoid and lignans may be presented in the form of a foodstuff which is consumed by the patient.
- iso-flavonoid and lignans eg enterolactone and/or enterodiol
- lignans eg enterolactone and/or enterodiol
- the present invention provides the use of soya-components as a source of iso-flavonoids in the manufacture of a medicament to combat cancer, benign prostatic hyperplasia, cardiovascular disease and postmenopausal symptoms.
- the present invention also provides the use of rye and/or flaxseed components as a source of lignans (eg enterolactone and/or enterodiol) in the manufacture of a medicament to combat cancer, benign prostate hyperplasia, cardiovascular disease and post-menopausal symptoms .
- lignans eg enterolactone and/or enterodiol
- composition of embodiments of the present invention are set out in the Examples.
- EXAMPLE 1 A cookie type composition was produced by blending the ingredients set out in the table below and cooking the blended product (for example 180-220°C for 20-40 minutes) . Conveniently, a batch of mixture may be made by multiplying the quantities of said ingredients, cooking the mixture in a suitable tray or container, and dividing the mixture into conveniently sized cookies.
- a cookie type composition was produced by blending the ingredients set out in the table below and cooking the blended product (for example 180-220°C for 20-40 minutes) .
- a cookie type composition was produced by blending the ingredients set out in the table below and cooking the blended product (for example 180-220°C for 20-40 minutes) .
- a cookie type composition was produced by blending the ingredients set out in the table below and cooking the blended product (for example 180-220°C for 20-40 minutes) .
- a cookie type composition was produced by blending the ingredients set out in the table below and cooking the blended product (for example 180-220°C for 20-40 minutes) .
- a cookie type composition was produced by blending the ingredients set out in the tableb below and cooking the blended product (for example 180-220°C for 20-40 minutes) .
- a cookie type composition was produced by blending the ingredients set out in the table below and cooking the blended product (for example 180-220°C for 20-40 minutes) .
- a cookie type composition was produced by blending the ingredients set out in the table below and cooking the blended product (for example 180-220°C for 20-40 minutes) .
- a cookie type composition was produced by blending the ingredients set out in the table below and cooking the blended product (for example 180-220°C for 20-40 minutes) .
- the cookies of the present invention illustrated may have a nutritional content as set out below:
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
L'invention porte sur une composition et une méthode de traitement servant à combattre certains états morbides, tels que le cancer et spécialement avant que lesdits états ne soient cliniquement détectables, ou alors à un stade peu avancé. Ladite composition a le pouvoir d'élever les niveaux d'iso-flavonoïdes (par exemple la génistéine) et de lignanes (par exemple des entérolactones) du corps à des niveaux d'efficacité thérapeutique. Ladite composition qui se présente sous forme d'aliment sous la forme pratique d'un biscuit ou d'un petit gâteau, comporte un constituant de soja, associé à un constituant de graine de lin, et/ou à un constituant de seigle.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU21009/97A AU2100997A (en) | 1996-03-08 | 1997-03-10 | Composition containing iso-flavonoids and lignans |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9604945.7 | 1996-03-08 | ||
| GBGB9604945.7A GB9604945D0 (en) | 1996-03-08 | 1996-03-08 | Composition |
| GB9610768.5 | 1996-05-23 | ||
| GBGB9610768.5A GB9610768D0 (en) | 1996-05-23 | 1996-05-23 | Composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1997032593A2 true WO1997032593A2 (fr) | 1997-09-12 |
| WO1997032593A3 WO1997032593A3 (fr) | 1997-10-30 |
Family
ID=26308892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB1997/000622 WO1997032593A2 (fr) | 1996-03-08 | 1997-03-10 | Composition contenant des iso-flavonoides et des lignanes |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2100997A (fr) |
| WO (1) | WO1997032593A2 (fr) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0906761A2 (fr) * | 1997-10-02 | 1999-04-07 | Archer-Daniels-Midland Company | Procédé de préparation et d'utilisation de produits phytochimiques |
| EP0954984A1 (fr) * | 1998-05-04 | 1999-11-10 | Källna Specialprodukter AB | Composition diététique contenant des fibres |
| US6391310B1 (en) | 1996-03-13 | 2002-05-21 | Archer Daniels Midland Company | Method of preparing and using isoflavones for the treatment of neurological symptoms |
| WO2002067700A1 (fr) * | 2001-02-26 | 2002-09-06 | Oriola Oy | Aliment fonctionnel et son procede de preparation |
| US6451849B1 (en) | 1999-03-30 | 2002-09-17 | Hormos Nutraceutical Oy Ltd. | Use of hydroxymatairesinol for prevention of cancers, non-cancer, hormone dependent diseases and cardiovascular diseases by hydroxymatairesinol, and a pharmaceutical preparation, food additive and food product comprising hydroxymatairesinol |
| US6689809B2 (en) | 1999-03-30 | 2004-02-10 | Hormos Nutraceutical Oy Ltd. | Food additive or product or a pharmaceutical preparation, comprising hydroxymatairesinol |
| EP1629723A1 (fr) * | 2004-08-25 | 2006-03-01 | Oriola, OY | Aliment fonctionnel et son utilisation |
| WO2006072647A1 (fr) * | 2005-01-10 | 2006-07-13 | Hormos Medical Ltd. | Emploi d'une lignane dans l'élaboration d'une préparation destinée à prévenir ou soulager les symptômes d'une insuffisance en oestrogènes |
| WO2012131639A1 (fr) | 2011-04-01 | 2012-10-04 | Funcional Food Research S.R.L. | Aliment fonctionnel pour femme comprenant du trèfle violet |
| CN108208076A (zh) * | 2018-01-09 | 2018-06-29 | 广州聚澜健康产业研究院有限公司 | 一种巧克力舒芙蕾及其制备方法 |
| WO2023068778A1 (fr) * | 2021-10-18 | 2023-04-27 | 리누 바이오 헬스 엘티디. | Composition pour la prévention et le traitement de maladies de la ménopause chez la femme comprenant un élément phytogène en tant que principe actif |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4001905A1 (de) * | 1990-01-24 | 1991-07-25 | Wilhelm Menge | Verfahren zum herstellen einer backware |
-
1997
- 1997-03-10 WO PCT/GB1997/000622 patent/WO1997032593A2/fr active Application Filing
- 1997-03-10 AU AU21009/97A patent/AU2100997A/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4001905A1 (de) * | 1990-01-24 | 1991-07-25 | Wilhelm Menge | Verfahren zum herstellen einer backware |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900240B2 (en) | 1996-03-13 | 2005-05-31 | Archer-Daniels-Midland Company | Method of preparing and using compositions extracted from vegetable matter for the treatment of cancer |
| US6399072B1 (en) | 1996-03-13 | 2002-06-04 | Archer Daniels Midland Company | Method of preparing and using isoflavones for the treatment of alcoholism |
| US6395279B1 (en) | 1996-03-13 | 2002-05-28 | Archer Daniels Midland Company | Method of preparing and using isoflavones for the treatment of cancer |
| US6261565B1 (en) | 1996-03-13 | 2001-07-17 | Archer Daniels Midland Company | Method of preparing and using isoflavones |
| US6391310B1 (en) | 1996-03-13 | 2002-05-21 | Archer Daniels Midland Company | Method of preparing and using isoflavones for the treatment of neurological symptoms |
| US6391308B1 (en) | 1996-03-13 | 2002-05-21 | Archer Daniels Midland Company | Method of preparing and using isoflavones for the treatment of blood related illnesses |
| US6391309B1 (en) | 1996-03-13 | 2002-05-21 | Archer Daniesl Midland Company | Method of preparing and using isoflavones for the treatment of female symptoms |
| US6518319B1 (en) | 1996-03-13 | 2003-02-11 | Archer Daniels Midland Company | Method of preparing and using compositions extracted from vegetable matter for the treatment of female symptoms |
| US6509381B2 (en) | 1996-03-13 | 2003-01-21 | Archer Daniels Midland Company | Method of preparing and using compositions extracted from vegetable matter for the treatment of neurological conditions |
| EP1466609A1 (fr) * | 1997-10-02 | 2004-10-13 | Archer-Daniels-Midland Company | Procédé de préparation et d'utilisation d'isoflavones |
| EP0906761A3 (fr) * | 1997-10-02 | 1999-05-19 | Archer-Daniels-Midland Company | Procédé de préparation et d'utilisation de produits phytochimiques |
| EP0906761A2 (fr) * | 1997-10-02 | 1999-04-07 | Archer-Daniels-Midland Company | Procédé de préparation et d'utilisation de produits phytochimiques |
| EP0954984A1 (fr) * | 1998-05-04 | 1999-11-10 | Källna Specialprodukter AB | Composition diététique contenant des fibres |
| US6689809B2 (en) | 1999-03-30 | 2004-02-10 | Hormos Nutraceutical Oy Ltd. | Food additive or product or a pharmaceutical preparation, comprising hydroxymatairesinol |
| US7005447B2 (en) | 1999-03-30 | 2006-02-28 | Hormos Nutraceutical Oy Ltd. | Food product comprising hydroxymatairesinol |
| US6451849B1 (en) | 1999-03-30 | 2002-09-17 | Hormos Nutraceutical Oy Ltd. | Use of hydroxymatairesinol for prevention of cancers, non-cancer, hormone dependent diseases and cardiovascular diseases by hydroxymatairesinol, and a pharmaceutical preparation, food additive and food product comprising hydroxymatairesinol |
| WO2002067700A1 (fr) * | 2001-02-26 | 2002-09-06 | Oriola Oy | Aliment fonctionnel et son procede de preparation |
| EP1629723A1 (fr) * | 2004-08-25 | 2006-03-01 | Oriola, OY | Aliment fonctionnel et son utilisation |
| WO2006072647A1 (fr) * | 2005-01-10 | 2006-07-13 | Hormos Medical Ltd. | Emploi d'une lignane dans l'élaboration d'une préparation destinée à prévenir ou soulager les symptômes d'une insuffisance en oestrogènes |
| JP2008526819A (ja) * | 2005-01-10 | 2008-07-24 | ホルモス メディカル リミテッド | エストロゲン欠乏に関連する症状を予防または改善するための組成物を製造するためのリグナンの使用 |
| WO2012131639A1 (fr) | 2011-04-01 | 2012-10-04 | Funcional Food Research S.R.L. | Aliment fonctionnel pour femme comprenant du trèfle violet |
| CN108208076A (zh) * | 2018-01-09 | 2018-06-29 | 广州聚澜健康产业研究院有限公司 | 一种巧克力舒芙蕾及其制备方法 |
| WO2023068778A1 (fr) * | 2021-10-18 | 2023-04-27 | 리누 바이오 헬스 엘티디. | Composition pour la prévention et le traitement de maladies de la ménopause chez la femme comprenant un élément phytogène en tant que principe actif |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997032593A3 (fr) | 1997-10-30 |
| AU2100997A (en) | 1997-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Desmawati et al. | Phytoestrogens and their health effect | |
| Slavin et al. | Whole‐grain consumption and chronic disease: protective mechanisms | |
| US5498631A (en) | Method for treatment of menopausal and premenstrual symptoms | |
| Slavin et al. | Plausible mechanisms for the protectiveness of whole grains | |
| Madhusudhan | Potential benefits of flaxseed in health and disease-A perspective | |
| Messina et al. | The health effects of soy: A reference guide for health professionals | |
| US5543146A (en) | Dietary supplement for alleviating the symptoms associated with enlargement of the prostate gland | |
| WO2010025605A1 (fr) | Aliment naturel fonctionnel nanométrique et son procédé de traitement | |
| Yu et al. | Beneficial health properties of psyllium and approaches to improve its functionalities | |
| WO1997032593A2 (fr) | Composition contenant des iso-flavonoides et des lignanes | |
| Awulachew | The role of wheat in human nutrition and its medicinal value | |
| AU2016253140B2 (en) | Plant extracts for the treatment of excess weight and obesity | |
| KR19990084077A (ko) | 비만개선을 위한 저당식 기능성 식품 | |
| Kahlon et al. | Effect of wheat bran fiber and bran particle size on fat and fiber digestibility and gastrointestinal tract measurements in the rat | |
| Ganguly et al. | Flaxseed (Linum usitatissimum) | |
| KR100602281B1 (ko) | 인삼가공절편이 포함된 선식의 조성물 및 이를 이용한다이어트 선식 조성물 | |
| Mayo | A natural approach to menopause | |
| CN110638038A (zh) | 一种用于控制高血糖的医学配方营养代餐粉及其制备方法 | |
| US20040202732A1 (en) | Composition to promote weight loss | |
| CN109758542A (zh) | 具有健胃作用的复合木香油脂肪乳制剂及制备方法与应用 | |
| CN104855877A (zh) | 一种红薯扁豆猕猴桃保健营养粉及其制作方法 | |
| WO2017019213A1 (fr) | Composition et procédé pour traiter et soulager les symptômes de bouffées de chaleur chez un sujet de sexe féminin | |
| Thompson | Role of lignans in carcinogenesis | |
| WO2024201515A1 (fr) | Formulation à base d'herbes efficace pour l'hypertension pulmonaire et le dysfonctionnement érectile | |
| KR20020089251A (ko) | 다이어트에 유용한 첩부용 조성물 및 첩부제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1997906264 Country of ref document: EP |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1997906264 Country of ref document: EP |
|
| NENP | Non-entry into the national phase in: |
Ref country code: JP Ref document number: 97531581 Format of ref document f/p: F |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase |